Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer: Tumours addicted to drugs are vulnerable.

Literature DB >> 28976969

Cancer: Tumours addicted to drugs are vulnerable.

Rebecca J Lee¹, Richard Marais¹.

Abstract

Entities: Disease

Mesh：
Humans
Neoplasms

Year: 2017 PMID： 28976969 DOI： 10.1038/nature24148

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

Keyword Cloud
References

× No keyword cloud information.

6 in total

1. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF^V600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Authors: Max Schreuer; Yanina Jansen; Simon Planken; Ines Chevolet; Teofila Seremet; Vibeke Kruse; Bart Neyns
Journal: Lancet Oncol Date: 2017-03-04 Impact factor: 41.316

2. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Authors: Levi A Garraway; Hans R Widlund; Mark A Rubin; Gad Getz; Aaron J Berger; Sridhar Ramaswamy; Rameen Beroukhim; Danny A Milner; Scott R Granter; Jinyan Du; Charles Lee; Stephan N Wagner; Cheng Li; Todd R Golub; David L Rimm; Matthew L Meyerson; David E Fisher; William R Sellers
Journal: Nature Date: 2005-07-07 Impact factor: 49.962

3. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Authors: Judith Müller; Oscar Krijgsman; Jennifer Tsoi; Lidia Robert; Willy Hugo; Chunying Song; Xiangju Kong; Patricia A Possik; Paulien D M Cornelissen-Steijger; Marnix H Geukes Foppen; Kristel Kemper; Colin R Goding; Ultan McDermott; Christian Blank; John Haanen; Thomas G Graeber; Antoni Ribas; Roger S Lo; Daniel S Peeper
Journal: Nat Commun Date: 2014-12-15 Impact factor: 14.919

Cancer: Tumours addicted to drugs are vulnerable.

1. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF^V600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

2. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

3. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

4. In vivo switching of human melanoma cells between proliferative and invasive states.

5. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

6. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

Cancer: Tumours addicted to drugs are vulnerable.

1. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

2. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

3. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

4. In vivo switching of human melanoma cells between proliferative and invasive states.

5. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

6. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

1. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF^V600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.